| Followers | 8 |
| Posts | 750 |
| Boards Moderated | 0 |
| Alias Born | 10/19/2008 |
Tuesday, February 18, 2014 2:34:53 PM
Oh it will be over!
Effecively and methaphorically, the analogy is quite good. Nanoviricides are indeeed a game changer. Even if they were only to work in animals. Which I guess us hubris hummans are not within that group of life forms, it would be wonderous. e.g. - Kill bird flu before it gets to be such an epedimical loading point. Stop or mitigate them that way if nothing else for crying out loud!
It has not been that long since NNVC has been on the NY market exchange. The science will be securitized by more who have serious interest in it. All indications to date is that the science has a great position of strength to endure such.
And yes, if that means it is too good to be true, well, maybe this time it is not. It is likely too good and too true. I guess let the parasitic ‘swing traders’ do their thing. Let them post manipulative statements and play their game. Long term this is the most interesting company I have seen in 40 years of investing. It really does have a potential wild card in its technology. It may take newcomers a while to digest it all, but the truth of nanoviricide efficacy will prevail.
In the true long run though, none of us make it out alive, so yes, it will eventually be over!
Have a great day!
HS
Effecively and methaphorically, the analogy is quite good. Nanoviricides are indeeed a game changer. Even if they were only to work in animals. Which I guess us hubris hummans are not within that group of life forms, it would be wonderous. e.g. - Kill bird flu before it gets to be such an epedimical loading point. Stop or mitigate them that way if nothing else for crying out loud!
It has not been that long since NNVC has been on the NY market exchange. The science will be securitized by more who have serious interest in it. All indications to date is that the science has a great position of strength to endure such.
And yes, if that means it is too good to be true, well, maybe this time it is not. It is likely too good and too true. I guess let the parasitic ‘swing traders’ do their thing. Let them post manipulative statements and play their game. Long term this is the most interesting company I have seen in 40 years of investing. It really does have a potential wild card in its technology. It may take newcomers a while to digest it all, but the truth of nanoviricide efficacy will prevail.
In the true long run though, none of us make it out alive, so yes, it will eventually be over!
Have a great day!
HS
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
